Volume 28, Issue 4 (Autumn 2022)                   Intern Med Today 2022, 28(4): 498-513 | Back to browse issues page


XML Persian Abstract Print


1- Department of Biochemistry, Faculty of Biological Sciences, North Tehran Branch, Islamic Azad University, Tehran, Iran.
2- Department of Medical Biotechnology, Biotechnology Research Center, Laboratory of Venom and Therapeutic Biomolecule, Pasteur Institute of Iran, Tehran, Iran.
3- Department of Medical Biotechnology, Biotechnology Research Center, Laboratory of Venom and Therapeutic Biomolecule, Pasteur Institute of Iran, Tehran, Iran. , behdani@pasteur.ac.ir
Abstract:   (256 Views)
Aims Programmed cell death protein-1 (PD-1) is a membrane receptor expressed on the surface of T and B lymphocytes, monocytes, natural killers, and dendritic cells. In cancer, the PD-1/PD-L1 system prevents the proliferation of T lymphocytes and causes the release of cytokines and cytotoxicity, which leads to the apoptosis of tumor-specific T cells, thereby preventing the immune response to cancer cells. 
Methods & Materials In this study, the extracellular part of the humanized PD-1 protein was cloned and expressed, and the protein was injected as an antigen into a camel (Camelus dromedarius) to obtain a camel polyclonal antibody against PD-1 protein. 
Findings The obtained results indicate the proper expression of the protein in the prokaryotic system. Also, using various tests, such as ELISA and western blot, it was confirmed that the polyclonal antibody obtained from camel can identify PD-1 protein. 
Conclusion This study showed that because of the advantages, such as the ability to bind multiple epitopes, camel polyclonal antibodies can be used in antibody-based research for effective and strong molecular applications to detect PD-1 receptors. 
Full-Text [PDF 5775 kb]   (122 Downloads) |   |   Full-Text (HTML)  (89 Views)  
Type of Study: Original | Subject: Basic Medical Science
Received: 2022/08/31 | Accepted: 2022/09/23 | Published: 2022/09/23

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.